Impact of changes in the WHO's 2019 update of DDDs on the measurement of adult hospital antibacterial consumption in Catalonia, 2008-18 by Grau, Santiago et al.
See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/344693384
Impact of changes in the WHO’s 2019 update of DDDs on the measurement of
adult hospital antibacterial consumption in Catalonia (Spain), 2008–18







Some of the authors of this publication are also working on these related projects:
Surveillance of Surgical site infections View project





All content following this page was uploaded by Enrique Limón on 16 October 2020.
The user has requested enhancement of the downloaded file.
Impact of changes in the WHO’s 2019 update of DDDs on the
measurement of adult hospital antibacterial consumption in Catalonia
(Spain), 2008–18
Santiago Grau1, Sergi Hernández 2*, Enric Limón2, Esther Calbo2,3 and Juan P. Horcajada4 on behalf of the
Catalan Infection Control and Antimicrobial Stewardship National Program (VINCat-PROA)†
1Service of Pharmacy, Hospital del Mar, Infectious Pathology and Antimicrobials Research Group, Institut Hospital del Mar
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Mútua Terrassa, Barcelona, Spain; Universitat Internacional de Catalunya, Barcelona, Spain; 4Service of Infectious Diseases, Hospital
del Mar, Infectious Pathology and Antimicrobials Research Group, Institut Hospital del Mar d’Investigacions Mèdiques (IMIM),
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Objectives: In 2019 the WHO fully adopted new DDD values. The objective of this study is to analyse their impact
on the measurement of consumption of antibacterials in hospitals participating in the Catalan Infection Control
and Antimicrobial Stewardship National Program (VINCat-PROA) in Catalonia (Spain) between 2008 and 2018.
Methods: The anatomical therapeutic chemical/DDD system was used to monitor adult hospital antibacterial
consumption expressed in DDD/100 bed-days. Consumption from 2008 to 2018 was calculated using both pre-
and post-update DDD values. Differences were calculated as the percentage variation in DDD/100 bed-days
and analysed with Student’s t-test. Simple linear regressions were performed to evaluate the trends in adult
antimicrobial consumption over the study period.
Results: The overall consumption according to post-update DDD values decreased by 12.2% (P , 0.001) com-
pared with the pre-update DDD values. Penicillins (#19.6.%; P , 0.001) and carbapenems (#19.0%; P"0.023)
showed the greatest reduction, followed by cephalosporins (#7.7%; P"0.021) and quinolone antibacterials
(#7.7%; P"0.017). ICU services showed the greatest overall reduction (#13.1%; P , 0.001). From 2008 to 2018
there was a statistically significant decrease in consumption of penicillins and quinolone antibacterials and a
statistically significant increase in cephalosporin and carbapenem consumption with both pre- and post-update
DDD values. There were no variations in the ranking of consumption between the pre- and post-update DDD
values.
Conclusions: The WHO’s updates of DDDs have had a significant impact on the measurement of antibacterial
consumption. In our region, they have corrected an overestimation of penicillin and carbapenem consumption
amounting to 19%. It is essential to bear these findings in mind for an accurate assessment of temporal trends
and benchmarking.
Introduction
WHO1 and ECDC2 agree that the analysis of the consumption of
antibacterials is crucial in order to optimize their use and to
bring down resistance rates. A relationship between the use
of certain antimicrobials and increased resistance has been
proposed.3
The anatomical therapeutic chemical/DDD (ATC/DDD) system,
developed and updated by the WHO Collaborating Centre for Drug
Statistics Methodology, has become an international standard for
drug metrics and facilitates the presentation and comparison of
drug consumption statistics at international, national and regional
levels.4 In 2008 the Catalan Infection Control and Antimicrobial
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Stewardship National Program (VINCat-PROA) adopted the ATC/
DDD system as a standardized measure.
In 2018, the WHO International Working Group for Drug
Statistics Methodology updated the DDD of eight commonly used
antibiotics as a result of a review of the doses used in clinical
practice. These new DDD values were fully adopted in 2019.5
The objective of this study is to analyse the impact of these
changes on the measurement of the consumption of hospital anti-
bacterials for systemic use by adults in Catalonia (Spain) between
2008 and 2018.
Materials and methods
During the study period the number of hospitals participating in VINCat-
PROA rose from 46 in 2008 to 63 in 2018. These figures represented 68.8%
and 85.7% of all adult acute hospital beds in Catalonia (a region of 7.6 mil-
lion people), respectively. The number of bed-days recorded increased from
2 991 053 in 2008 to 3 714 938 in 2018.
The ATC/DDD system was used to monitor adult hospital antibacterial
consumption.6 The pharmacy departments at the participating hospitals
reported the number of units of each antibacterial for systemic use (J01)
dispensed and bed-days data from the whole hospital and from the medic-
al and surgical services and ICUs. Annual antibacterial consumption,
expressed in DDD/100 bed-days, was calculated using both pre-update
DDD values (WHO ATC/DDD index 2017) and post-update DDD values
(WHO ATC/DDD index 2019), keeping the number of units used and bed-
days of every single year.
The percentage difference in mean consumption between pre- and
post-update DDD values was calculated and the significance of differences
between values was established by Student’s t-test. Simple linear regres-
sions were performed to evaluate the trends in consumption over the study
period. The linear relationship was checked by ANOVA tests, and Pearson’s
correlation coefficients (Pc values) were obtained. Values of P , 0.05 were
considered statistically significant. A two-tailed distribution was assumed
for all P values.
Results
Impact of DDD update on the mean consumption of
antibacterials for systemic use
During 2008–18 the overall mean adult hospital antibacterial con-
sumption calculated with post-update DDD values decreased by
12.2% (P , 0.001) compared with the pre-update DDD values: 79.4
versus 69.7 DDD/100 bed-days (Table 1). Penicillins showed the
greatest reduction [#19.6% (P , 0.001), 31.7 versus 25.5 DDD/
100 bed-days], followed by carbapenems [#19.0% (P"0.023),
5.4 versus 4.4 DDD/100 bed-days], cephalosporins [#7.7%
(P"0.021), 13.8 versus 12.7 DDD/100 bed-days] and quinolone
antibacterials [#7.7% (P"0.017), 12.3 versus 11.3 DDD/100 bed-
days].
Mean consumption decrease in all services and ICUs showed
the greatest overall reduction (#13.1%, P , 0.001). In ICUs, carba-
penems were the most affected by the update (#25.1%,
P , 0.001). Penicillins had the greatest reduction in both medical
(#20.9%, P , 0.001) and surgical services (#18.4%, P , 0.001).
Ampicillin and colistin had the largest reductions in consump-
tion (#66.4%, P , 0.001 and #59.6%, P , 0.001, respectively);
however, amoxicillin/b-lactamase inhibitors showed the greatest
impact in terms of overall reduction in consumption, due to its
extended use (25.3% and 23.0% of the total antibacterial
consumption with pre- and post-update DDD values, respectively).
Antibiotics of special interest such as meropenem (#31.6%,
P"0.03) and cefepime (#50.1%, P , 0.001) also presented not-
able reductions in consumption.
Impact of DDD update on the evolution of consumption
of antibacterials for systemic use
From 2008 to 2018 (Figure 1, annual overall consumption data on
demand) there was a decrease in consumption of penicillins with
both pre-update DDD values (33.5 versus 29.4 DDD/100 bed-days,
Pc"#0.92, P , 0.001) and post-update DDD values (26.10 versus
24.24 DDD/100 bed-days, Pc"#0.72, P"0.012). Differences
between pre- and post-update values showed a reduction
from#22.2% in 2008 to#17.5% in 2018, mainly due to a decrease
in amoxicillin/b-lactamase inhibitor consumption (23.6 versus
17.3 DDD/100 bed-days with pre-update DDD values, and 17.8
versus 14.2 DDD/100 bed-days with post-update DDD values).
Consumption of quinolone antibacterials showed a statistically
significant reduction with both pre-update (12.4 versus 10.4 DDD/
100 bed-days, Pc"#0.76, P , 0.001) and post-update values (11.6
versus 9.6 DDD/100 bed-days, Pc"#0.78, P"0.004). Differences
increased from#5.9% in 2008 to#7.5% in 2018.
Cephalosporin consumption increased from 2008 to 2018 with
both pre-update (12.0 versus 14.7 DDD/100 bed-days, Pc"0.94,
P , 0.001) and post-update DDD values (10.9 versus 13.9 DDD/100
bed-days, Pc"0.95, P , 0.001). Differences fell from #9.5% in
2008 to #5.5% in 2018, mainly due to an increase in cefazoline
(1.9 versus 3.3 DDD/100 bed-days) and ceftriaxone (3.8 versus
5.5 DDD/100 bed-days) consumption and the maintenance of
cefepime consumption both pre-update (1.6 versus 1.6 DDD/
100 bed-days) and post-update (0.7 versus 0.7 DDD/100 bed-
days).
Consumption of carbapenems increased from 2008 to 2018
with both pre-update (3.4 versus 6.9 DDD/100 bed-days,
Pc"0.99, P , 0.001) and post-update DDD values (3.4 versus
5.4 DDD/100 bed-days, Pc"0.99, P , 0.001). Differences rose
from #3.5% in 2008 to #22.3% in 2018, due to a reduction in
imipenem consumption (1.8 versus 0.9 DDD/100 bed-days)
combined with an increase in meropenem consumption with both
pre-update (1.2 versus 4.6 DDD/100 bed-days) and post-update
DDD values (1.1 versus 3.1 DDD/100 bed-days).
Impact of DDD update on relative consumption of
antibacterials for systemic use
There were no variations in the ranking of consumption between
the pre- and post-update DDD values regarding the total con-
sumption of all antibiotic groups during the study period. Penicillins
were the most used and represented 35.0% and 32.2% of the total
adult hospital antibacterial consumption with both pre- and post-
update DDD values, followed by cephalosporins (17.5% and
18.4%, respectively) and quinolone antibacterials (12.4% and
12.8%, respectively). The group ‘other antibacterials’ (J01X) occu-
pied the fourth place (11.7% and 12.5%, respectively) followed by
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Total J01 Antibacterials for systemic use 79.44 (2.13) 69.75 (2.51) 12.2 ,0.001
J01C Penicillins 31.66 (1.67) 25.46 (0.83) 19.6 ,0.001
J01CA01 Ampicillin 2.38 (0.24) 0.80 (0.08) 66.4 ,0.001
J01CA04 Amoxicillin 1.59 (0.27) 1.06 (0.16) 33.6 ,0.001
J01CR02 Amoxicillin/b-lactamase inhibitor 20.14 (2.24) 16.06 (1.22) 20.3 ,0.001
J01DBCDE Cephalosporins 13.80 (0.90) 12.73 (1.09) 7.7 0.021
J01DE01 Cefepime 1.76 (0.14) 0.88 (0.09) 50.1 ,0.001
J01DH Carbapenems 5.40 (1.18) 4.37 (0.73) 19.0 0.023
J01DH02 Meropenem 3.15 (1.19) 2.15 (0.71) 31.6 0.030
J01M Quinolone antibacterials 12.29 (0.91) 11.34 (0.79) 7.7 0.017
J01MA02 Ciprofloxacin 5.80 (0.59) 4.91 (0.52) 15.3 0.001
J01XB01 Colistin 0.75 (0.12) 0.31 (0.10) 59.6 ,0.001
ICU J01 Antibacterials for systemic use 143.65 (4.32) 124.78 (3.70) 13.1 ,0.001
J01C Penicillins 42.89 (3.62) 37.47 (2.81) 12.6 0.001
J01CA01 Ampicillin 4.79 (0.43) 1.59 (0.12) 66.9 ,0.001
J01CA04 Amoxicillin 1.11 (0.46) 0.71 (0.27) 36.1 ,0.001
J01CR02 Amoxicillin/b-lactamase
inhibitor
17.10 (2.70) 15.45 (1.81) 9.7 0.022
J01DBCDE Cephalosporins 22.71 (1.21) 19.72 (0.85) 13.1 ,0.001
J01DE01 Cefepime 5.54 (1.14) 2.66 (0.47) 50.2 ,0.001
J01DH Carbapenems 20.49 (2.64) 15.35 (1.16) 25.1 ,0.001
J01DH02 Meropenem 15.38 (4.21) 10.36 (2.41) 32.7 ,0.001
J01M Quinolone antibacterials 13.94 (1.24) 12.03 (1.24) 13.6 0.002
J01MA02 Ciprofloxacin 6.93 (0.91) 4.82 (0.71) 30.5 ,0.001
J01XB01 Colistin 5.32 (1.01) 1.99 (0.52) 62.6 ,0.001
Medical J01 Antibacterials for systemic use 78.99 (2.79) 69.14 (1.94) 12.5 ,0.001
J01C Penicillins 33.04 (2.23) 26.12 (1.32) 20.9 ,0.001
J01CA01 Ampicillin 2.36 (0.31) 0.81 (0.08) 65.8 ,0.001
J01CA04 Amoxicillin 1.87 (0.34) 1.24 (0.20) 33.6 ,0.001
J01CR02 Amoxicillin/b-lactamase
inhibitor
21.86 (2.63) 17.01 (1.54) 22.2 ,0.001
J01DBCDE Cephalosporins 13.80 (0.90) 12.73 (1.09) 10.3 0.002
J01DE01 Cefepime 2.44 (0.21) 1.19 (0.11) 51.2 ,0.001
J01DH Carbapenems 4.78 (1.19) 4.00 (0.73) 16.4 0.078
J01DH02 Meropenem 2.63 (1.01) 1.86 (0.54) 29.2 ,0.001
J01M Quinolone antibacterials 14.61 (1.20) 13.98 (1.02) 4.3 0.197
J01MA02 Ciprofloxacin 4.57 (0.46) 3.93 (0.41) 13.7 0.003
J01XB01 Colistin 0.70 (0.14) 0.29 (0.12) 58.4 ,0.001
Surgical J01 Antibacterials for systemic use 74.76 (3.86) 66.55 (4.38) 11.0 ,0.001
J01C Penicillins 29.78 (1.19) 24.38 (0.82) 18.4 ,0.001
J01CA01 Ampicillin 2.31 (0.23) 0.78 (0.09) 66.4 ,0.001
J01CA04 Amoxicillin 1.48 (0.29) 0.97 (0.15) 34.8 ,0.001
J01CR02 Amoxicillin/b-lactamase
inhibitor
18.68 (1.64) 15.27 (0.82) 18.2 ,0.001
J01DBCDE Cephalosporins 14.34 (1.50) 13.81 (1.63) 3.7 0.443
J01DE01 Cefepime 0.69 (0.16) 0.34 (0.08) 51.3 ,0.001
J01DH Carbapenems 4.63 (0.99) 3.78 (0.64) 18.3 0.027
J01DH02 Meropenem 2.48 (0.97) 1.66 (0.61) 32.9 ,0.001
J01M Quinolone antibacterials 9.39 (0.69) 8.36 (0.71) 10.9 0.003
J01MA02 Ciprofloxacin 7.12 (0.69) 6.09 (0.66) 14.5 0.002
J01XB01 Colistin 0.37 (0.12) 0.15 (0.07) 60.0 ,0.001
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Discussion
The reduction in the measurement of adult hospital antibacterial
consumption in our study (12.2%) is similar to that reported
by Robertson et al.,7 who estimated a total DDD per
1000 inhabitants-day reduction on average by 12.0%, and con-
firms that the WHO’s 2019 DDD update corrects an overestimation
of the consumption of antibacterials for systemic use (especially in
penicillins) that had already been detected by Haug and Reikvam8
in Norway, Charra et al.9 in France and the EU, and Klein et al.10 in
their study of antibiotic consumption in 76 countries.
Carbapenems (meropenem) were more affected by DDD changes
in ICU services since patients are more complex and the use
of broad-spectrum antibiotics is higher.
This reduction in the measurement related to the update of
DDD values did not affect the main trends in the evolution of
antibacterial consumption observed during our study period.
Similar reductions in penicillin use were observed by Dickstein
et al.11 in Israel and an increase in the consumption of first- and
third-generation cephalosporins was observed by Kwint et al.12 in
the Netherlands and Grau et al.13 in Catalonia. The reduction
in quinolone consumption from 2008 to 2018 observed with both
pre- and post-update DDD values could be related to the associ-
ation of fluoroquinolones with an increased risk of aortic aneurysm
and dissection.14 Meropenem is the only carbapenem affected by
the DDD update and the upward trend in its consumption, together
with the downward trend in the consumption of imipenem due
to adverse effects associated with its use,15 can explain the great
increase in the difference between the pre- and post-update
consumption in 2008 (#3.5%) and 2018 (#22.3%). Despite the
increase in the use of carbapenems, in the last few years their
consumption has stabilized throughout Europe.16
The changes in DDD values have not included other groups of
antibiotics such as tetracyclines (J01A), sulphonamides and tri-
methoprim (J01E), macrolides, lincosamides and streptogramins
(J01F), aminoglycoside antibacterials (J01G) or other antibacterials
(J01X); however, the general ranking of relative consumption has
not been affected. Penicillins and carbapenems presented the
largest relative reductions in the ranking of consumption in our
area since they were the ones most affected by the DDD changes.
Cephalosporins and quinolones increased their share of the total
since changes in DDDs affected them less and they continue to
be widely consumed. These results corroborate the estimations
published by Robertson et al.7
A limitation of this study is the increase in participating hospitals
between 2008 and 2018. This could have caused changes in
consumption patterns. However, high-complexity hospitals have
participated from the beginning and the use of average consump-
tion from the last 10 years contributes to mitigating the possible
selection bias.
In conclusion, the WHO’s updates of DDDs have had a signifi-
cant impact on the measurement of antibacterial consumption.
In our region, they have corrected an overestimation of penicillin
and carbapenem consumption amounting to 19%.
It is essential to bear these findings in mind for an accurate
assessment of temporal trends and benchmarking.
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Figure 1. Evolution of consumption of antibacterials for systemic use (J01) pre- and post-update of the WHO DDDs (Catalonia 2008–18). Percentages
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Clopès, Núria Ortı́, Teresa Guerrera, Sandra Barbadillo, David Brandariz,
Jordi Fernández, Ana Ayestaran, Oscar Pascual, Eduard Hidalgo, Flotats
Vidal, Elisenda, Daniel Serrano.
Funding
This study was carried out as part of our routine work. Antibacterial con-
sumption data had been collected as a part of VINCat-PROA. VINCat-
PROA is supported by public funding from the CatSalut, Department of




1 WHO. Surveillance of Antimicrobial Use. https://www.who.int/medicines/
areas/rational_use/AMU_Surveillance/en/.
2 ECDC. European Surveillance of Antimicrobial Consumption Network (ESAC-
Net). https://ecdc.europa.eu/en/about-us/partnerships-and-networks/dis
ease-and-laboratory-networks/esac-net.
3 Malik B, Bhattacharyya S. Antibiotic drug-resistance as a complex system
driven by socio-economic growth and antibiotic misuse. Sci Rep 2019; 9:
9788.
4 WHO. The ATC/DDD Methodology. https://www.who.int/medicines/regula
tion/medicines-safety/toolkit_methodology/en/.
5 WHO Collaborating Centre for Drug Statistics Methodology, Norwegian
Institute of Public Health. DDD Alterations from 2005-2020. WHO. https://
www.whocc.no/atc_ddd_alterations__cumulative/ddd_alterations/.
6 WHO Collaborating Centre for Drug Statistics Methodology, Norwegian
Institute of Public Health. Guidelines for ATC Classification and DDD
Assignment. WHO. https://www.whocc.no/atc_ddd_index_and_guidelines/
guidelines/.
7 Robertson J, Iwamoto K, Hoxha I et al. Antimicrobial medicines consump-
tion in Eastern Europe and Central Asia—an updated cross-national study
and assessment of quantitative metrics for policy action. Front Pharmacol
2019; 9: 1156.
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